Showing results (41-50 of 324) with videos related to
Sort By:
Pageof 33
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 6, 2016
Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-AnalysisChee Khoon Lee, Johnathan Man, Sally Lord, et al.Expert Review of Respiratory Medicine|December 9, 2016
New data on clinical decisions in NSCLC patients with uncommon EGFR mutationsTing-Hui Wu, Emily Han-Chung Hsiue, Jih-Hsiang Lee, et al.Investigational New Drugs|August 29, 2006
Arsenic trioxide in patients with hepatocellular carcinoma: a phase II trialChia-Chi Lin, Chiun Hsu, Chih-Hung Hsu, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|September 30, 2005
Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance statusWen-Pin Su, Chih-Hsin Yang, Chong-Jen Yu, et al.Future Oncology (London, England)|February 18, 2026
Time to achieve response and depth of maximal tumor response as potential surrogates for overall survival in advanced non-small cell lung cancerRachel Woodford, Sally Lord, Tom John, et al.Translational Lung Cancer Research|February 9, 2026
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic reviewRoss A Soo, Darren Wan-Teck Lim, James Chih-Hsin Yang, et al.Lung Cancer (Amsterdam, Netherlands)|April 15, 2005
Survival of stage IIIB/IV non-small cell lung cancer patients who received chemotherapy but did not participate in clinical trialsSung-Hsin Kuo, Chih-Hsin Yang, Chong-Jen Yu, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|January 29, 2025
Identification of the molecular characterization and tumor microenvironment of thoracic inflammatory myofibroblastic tumorsYen-Lin Huang, Chia-Chi Hsu, Derek De-Rui Huang, et al.Clinical Drug Investigation|December 17, 2017
Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKIHelen Mann, Frank Andersohn, Carolyn Bodnar, et al.Journal of the Formosan Medical Association = Taiwan Yi Zhi|May 26, 2010
Characteristics and risk factors of oxaliplatin-related hypersensitivity reactionsYu-Yun Shao, Fu-Chang Hu, Jin-Tung Liang, et al.Pageof 33